Clinical Trial Update: Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer [NA]

View source ↗

Summary

A Phase I/II neoadjuvant study evaluating cemiplimab in combination with dupilumab in patients with early-stage non-small cell lung cancer; the trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DUPIXENT (DUPILUMAB)
• Libtayo (cemiplimab)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Non-Small Cell Lung Cancer, Immunotherapy | NA | Status: NOT_YET_RECRUITING